Dexcom (DXCM) Notes Payables (2022 - 2025)

Dexcom (DXCM) posted quarterly Notes Payables of $1.2 billion for Q3 2025, little changed quarter-over-quarter from $1.2 billion in Q2 2025.

Dexcom (DXCM) Notes Payables (2022 - 2025) Analysis & Trends

Dexcom (DXCM) has reported Notes Payables for 4 consecutive years, with $1.2 billion the latest figure, recorded in Q3 2025.

In Q3 2025, Notes Payables changed N/A year-over-year to $1.2 billion; the TTM figure through Sep 2025 stood at $1.2 billion (changed N/A YoY), while the FY2024 annual figure was $1.2 billion, changed N/A from the prior year.
Notes Payables was little changed at $1.2 billion in Q3 2025 per DXCM's latest filing, from $1.2 billion in the prior quarter.
Across five years, Notes Payables topped out at $1.2 billion in Q3 2025 and bottomed at $124.2 million in Q3 2023.
Historically, Notes Payables has averaged $908.3 million across 4 years, with a median of $989.1 million in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.12 Bn	193.52 Bn	7.27 Bn
2	Stryker	128.79 Bn	125.32 Bn	4.50 Bn
3	Medtronic	119.30 Bn	110.08 Bn	6.41 Bn
4	Boston Scientific	73.50 Bn	72.96 Bn	3.85 Bn
5	Edwards Lifesciences	52.11 Bn	47.86 Bn	1.35 Bn
6	Dexcom	34.62 Bn	32.67 Bn	830.00 Mn
7	GE HealthCare Technologies	34.05 Bn	31.94 Bn	2.18 Bn
8	Koninklijke Philips	26.42 Bn	23.10 Bn	4.55 Bn
9	Steris	23.15 Bn	22.67 Bn	684.20 Mn
10	Zimmer Biomet Holdings	19.32 Bn	18.91 Bn	1.54 Bn

Download Data